MAP Pharmaceuticals Inc.  

(Public, NASDAQ:MAPP)   Watch this stock  
Find more results for MAPP
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -1.85
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -1437.59% -142.78%
Operating margin -1437.24% -141.55%
EBITD margin - -135.26%
Return on average assets -51.00% -34.65%
Return on average equity -139.42% -64.45%
Employees 121 -
CDP Score - -

Address

Suite 200, 2400 Bayshore Parkway
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-3863100 (Phone)
+1-650-3863101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.